Airdate: Thursday, April 28, 2022 Season: 9 Episode: 12
Guest: Bin Xie
Dr. Bin Xie from LIDE Biotech answers questions from a webinar where he discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
For more information or to watch the webinar, click here.
Associated Webinar: Current and Novel Immuno-Oncology Drug Evaluation Methods via Humanized Mouse Models
Similar Podcasts
#ExpertAnswers: Steven Loo-Yong-Kee on CRISPR-Edited T Cells
Steven Loo-Yong-Kee highlights Artisan Bio’s STAR-CRISPR system for optimized gene editing in cell therapy, with a focus on the genetic modification of T cells for cancer immunotherapy.
Talking Real Science with Ellie Siebeneck
Ellie Siebeneck is one of 10 winners of the inaugural Scientist.com STEM Research NIL Award. In this episode, she discusses her passion for learning, mentorship and where the road lies ahead for her academic journey.
Industry Insights with Crown Bioscience: Analyzing the Suppressive TME in In Vitro Based Assays
Nataliia Beztsinna and Marten Hornsveld from Crown Bioscience talk about native and reconstituted TME assays, how they can help in the preparation for clinical trials, and what kinds of therapies in development would benefit the most from this kind of testing.
Related Content
Exploring Predictive Biomarkers and ERK1/2 Phosphorylation: A New Horizon in Forecasting Survival and Response to Immune Checkpoint Blockade in Glioblastoma Treatment
In this webinar, Victor Arrieta highlights the link between p-ERK activation and improved survival in rGBM patients using anti-PD-1 immunotherapy.
Revolutionizing Immunotherapy Research with 3D, Multiplexed Cryo-fluorescence Tomography
Dr. Matt Silva showcases the power of cryo-fluorescence tomography (CFT) in advancing immunotherapy research.
Unlocking Spatial Insights: Accelerate Discoveries 70% Faster with SignalStar™ Multiplex IHC
Join us to learn how to accelerate spatial biology discoveries by 70% with optimized, ready-to-go panels using SignalStar™ Multiplex IHC.